Home The Word Brain My Amedeo FAQ Privacy About   


Hanzi Hunter — ultra-fast Hanzi study

All 1,152 characters from the aioLingua manual

Abstract • About • The 20 audio files

← aioLingua Chinese Online

← Chinese aioLingua PDF


  Bladder Cancer, November 2025

Free Subscription


Abstracts

Retrieve all available abstracts of the following 264 articles:
HTML format


 

Single Articles

  1. GUERRERO-RAMOS F, Schwenke C, Pinto A, Mulhern-Haughey S, et al
    Systematic Review of the Definition of Cure and of Curative-intent Treatments in Early Bladder Cancer.
    Eur Urol Oncol. 2025 Oct 30:S2588-9311(25)00256.
    PubMed    
    Abstract available

  2. BENNETT HO, Bogumil D, Kysh L, van den Brandt P, et al
    Systematic review and meta-analysis corrected for history of smoking tobacco identifies type 1 diabetes as a possible risk factor for bladder cancer.
    Diabetes Res Clin Pract. 2025 Oct 29:112976. doi: 10.1016/j.diabres.2025.112976.
    PubMed    
    Abstract available

  3. LIN J, Fu W, You C, Song X, et al
    Updated cost-effectiveness analysis of first-line novel therapies in locally advanced or metastatic urothelial carcinoma across the UK, US, and China.
    World J Urol. 2025;43:657.
    PubMed    
    Abstract available

  4. CHOI J, Park C, Lee KH, Kwak HJ, et al
    Comparison of Remimazolam and Sevoflurane on Perioperative Body Temperature Changes in Older Patients Undergoing Transurethral Resection of Prostate or Bladder Tumors Under General Anesthesia: A Randomized Prospective Clinical Trial.
    Clin Interv Aging. 2025;20:1811-1820.
    PubMed    
    Abstract available

  5. MENG R, Han Y, Zhai Z
    Analysis of risk factors for ureteral stricture and tumor recurrence after transurethral resection of bladder tumor in paraureteral bladder cancer.
    Front Surg. 2025;12:1680837.
    PubMed    
    Abstract available

  6. CUI S, Luo X, Fan G, Jiang J, et al
    A Novel FGFR3-Targeting Antibody-Drug Conjugate Induces Tumor Cell Apoptosis through the cGAS-STING Pathway in Bladder Cancer.
    Adv Sci (Weinh). 2025 Oct 30:e09933. doi: 10.1002/advs.202509933.
    PubMed    
    Abstract available

  7. MING J, Jin S, Liu Z, Yang K, et al
    Imidacloprid contributes to bladder cancer progression: preliminary evidence based on network toxicology, machine learning and molecular docking.
    BMC Pharmacol Toxicol. 2025;26:180.
    PubMed    
    Abstract available

  8. EGGER M, D'Andrea VD, Steiner C, Onochie NO, et al
    Optimizing local control in the surgical management of bladder cancer.
    Nat Rev Urol. 2025 Oct 30. doi: 10.1038/s41585-025-01098.
    PubMed    
    Abstract available

  9. SINGHAL S, Singhal S, Gardner KL, Dikshit A, et al
    A novel spatial framework to validate arsenic exposure gene expression profiling in bladder cancer using multiplex FISH and AI-powered digital pathology.
    Sci Rep. 2025;15:37925.
    PubMed    
    Abstract available

  10. COLSON M, Aubry A, Gaide N, Lluel P, et al
    Bacterial nanoparticles as a potent and safe alternative to BCG for bladder cancer immunotherapy.
    Cancer Gene Ther. 2025 Oct 30. doi: 10.1038/s41417-025-00984.
    PubMed    
    Abstract available

  11. CHEN KP, Liao TL, Hsu FT, Chen GH, et al
    miR-124 Targets EGFR and Attenuates Growth and Invasion in Bladder Cancer Cells.
    In Vivo. 2025;39:3216-3225.
    PubMed    
    Abstract available

  12. GAMBALE E, Giorgione R, Basso U, Galli L, et al
    A Snapshot from the Italian Clinical Practice Regarding Efficacy and Utility Rate of Perioperative Chemotherapy in Muscle-invasive Bladder Cancer: The RealBLADDER Study.
    In Vivo. 2025;39:3381-3393.
    PubMed    
    Abstract available

  13. YAN Y, Ahmed M, Mach KE, Liao JC, et al
    An Organoid Biosensing Platform for Personalized Prognosis of Bladder Cancer.
    ACS Nano. 2025 Oct 30. doi: 10.1021/acsnano.5c09883.
    PubMed    
    Abstract available

  14. HUSSAIN S, Carr A, Crabb SJ, Dodhia V, et al
    UK multidisciplinary recommendations on use of combination first-line enfortumab vedotin? and pembrolizumab in advanced urothelial carcinoma.
    Oncologist. 2025;30:oyaf220.
    PubMed    
    Abstract available

  15. NAGATA M, Kikuchi E, Ito T, Sato M, et al
    Avelumab Maintenance Therapy in Patients With Curatively Unresectable Urothelial Carcinoma in Japan: Subgroup Analyses of Post-Marketing Surveillance Data by Age, Prior Chemotherapy Regimen, and Best Overall Response to Prior Chemotherapy.
    Cancer Med. 2025;14:e71177.
    PubMed    
    Abstract available

  16. KIKUCHI E, Nagata M, Ito T, Sato M, et al
    Real-World Outcomes of Avelumab Maintenance Therapy in Patients With Curatively Unresectable Urothelial Carcinoma in Japan: Results From the Final Analysis of Postmarketing Surveillance.
    Cancer Med. 2025;14:e71264.
    PubMed    
    Abstract available


  17. EXPRESSION OF CONCERN: Long Non-coding RNA Urothelial Cancer-associated 1 Promotes Bladder Cancer Cell Migration and Invasion by Way of the hsa-miR-145-ZEB1/2-FSCN1 Pathway.
    Cancer Sci. 2025 Oct 29. doi: 10.1111/cas.70241.
    PubMed    


  18. HE W, Wang Z, Wang M, Chen Q, et al
    Prognostic significance of lymph node yield in pelvic lymph node dissection for bladder cancer: population-based study.
    World J Surg Oncol. 2025;23:405.
    PubMed    
    Abstract available

  19. YIN G, Zheng S, Wang J, Hua T, et al
    Comprehensive analysis of coagulation-associated gene signature in bladder cancer diagnosis, prognosis, and immunotherapy.
    Sci Rep. 2025;15:37768.
    PubMed    
    Abstract available

  20. FUJII N, Hirata H, Ban Y, Oka S, et al
    Extracellular vesicles-derived LncRNA MAFG-AS1 predicts clinical response to pembrolizumab in patients with advanced urothelial carcinoma.
    Mol Biol Rep. 2025;53:23.
    PubMed    
    Abstract available

  21. HUANG CS, Yu DS, Jiang SS, Wu YS, et al
    Extracellular Vesicle-Mediated Regulation of H3C14 Contributes to Gemcitabine Resistance in Bladder Cancer.
    J Extracell Vesicles. 2025;14:e70179.
    PubMed    
    Abstract available

  22. SUN Y, Liu X, He W
    Comment on "Correlation of noninvasive imaging of tumour-infiltrating lymphocytes with survival and BCG immunotherapy response in patients with bladder cancer: a multicentre cohort study".
    Int J Surg. 2025 Oct 28. doi: 10.1097/JS9.0000000000003680.
    PubMed    


  23. OKUR A, Sahin KC, Sahin Z, Gultekin MH, et al
    Leser-Trelat Sign as an Initial Manifestation of Synchronous Prostate and Bladder Cancer.
    Cureus. 2025;17:e93325.
    PubMed    
    Abstract available

  24. GAO W, Li Y, Fu Z, Gao Z, et al
    pQTL Mendelian randomization analysis combined with single-cell sequencing to identify biomarkers and drug targets for bladder cancer.
    Mol Clin Oncol. 2025;23:106.
    PubMed    
    Abstract available

  25. CLOUTIER F, Paquin A, Cloutier M, Oufqir Y, et al
    Exploring the Synthesis, Anti-Inflammatory and Anti-Tumor Potential of 4-Maleimidylphenyl-Hydrazide Derivatives.
    Molecules. 2025;30:4035.
    PubMed    
    Abstract available

  26. KRAEVSKA E, Popovska S
    Analysis of HER2 Expression in Different Histological Subtypes and IHC-Based Molecular Variants of Muscle-Invasive Bladder Carcinoma.
    Medicina (Kaunas). 2025;61:1759.
    PubMed    
    Abstract available

  27. DAMA M, Yorulmaz EM, Ozcan S, Kose O, et al
    AISI, SIRI, and MLR in Predicting Surgical Outcomes After Radical Cystectomy: Revisiting Inflammatory Risk Markers.
    Medicina (Kaunas). 2025;61:1756.
    PubMed    
    Abstract available

  28. OZTAN G, Issever H, Issever T, Sahin L, et al
    Lead Exposure and Bladder Cancer: Molecular Insights from TCGA RNA-Seq and Toxicogenomic Integration.
    Cancers (Basel). 2025;17:3291.
    PubMed    
    Abstract available

  29. WU J, Liu W
    Integrative Analysis of Biomarkers for Cancer Stem Cells in Bladder Cancer and Their Therapeutic Potential.
    Genes (Basel). 2025;16:1146.
    PubMed    
    Abstract available

  30. LIU F, Han L, Liu S, Wang C, et al
    Diseases burden and trends of bladder cancer attributable to behavioral and metabolic factors among global and Chinese population, 1990-2021: results from the global burden of disease study 2021.
    J Health Popul Nutr. 2025;44:377.
    PubMed    
    Abstract available

  31. SU X, Huang L, Yu Y, Zhang J, et al
    LINC01082 inhibits malignant phenotypes of bladder cancer through sponging miR-1269a.
    World J Surg Oncol. 2025;23:402.
    PubMed    
    Abstract available

  32. AYDIN R, Ergul RB, Tantekin A, Sanli Y, et al
    The utility of radiopharmaceutical uptake in the bladder neck and prostate on preoperative FDG PET/CT in determining urethral surgical margin positivity in patients undergoing radical cystoprostatectomy for bladder cancer.
    BMC Urol. 2025;25:271.
    PubMed    
    Abstract available

  33. VIERGEVER BJ, Zuidema AC, Jonges T, Van Schelven SJ, et al
    Molecular subtyping of advanced bladder cancer patients and patient-derived organoids based on a 3-marker immunohistochemistry approach to evaluate chemotherapy sensitivity.
    Urol Oncol. 2025 Oct 27:S1078-1439(25)00393.
    PubMed    
    Abstract available

  34. WONG R, Matulewicz RS, Bjurlin MA
    A Urologist's Guide to Managing Bladder Cancer in Patients Who Smoke.
    Eur Urol Focus. 2025 Oct 27:S2405-4569(25)00287.
    PubMed    
    Abstract available

  35. IDE H, Najafi MAE, Matsukawa T, Tatenuma T, et al
    Expression of Glucocorticoid Receptor and FOXO1/phospho-FOXO1 in Bladder Cancer as Independent Prognosticators.
    Cancer Genomics Proteomics. 2025;22:850-862.
    PubMed    
    Abstract available

  36. KABANOV D, Rubtsova N, Golbits A, Kaprin A, et al
    Radiomics-Based Preoperative Assessment of Muscle-Invasive Bladder Cancer Using Combined T2 and ADC MRI: A Multicohort Validation Study.
    J Imaging. 2025;11:342.
    PubMed    
    Abstract available

  37. EREN AE, Aydin AA, Aksaray EE, Durak A, et al
    Pan-Immune-Inflammation Value as a Predictor of Long-Term Outcomes in Patients with Urothelial Carcinoma of the Bladder: A Pilot Study.
    Curr Oncol. 2025;32:534.
    PubMed    
    Abstract available

  38. GOTI V, Raza MW, Singh A, Prasad SN, et al
    A Phase 2 Prospective Trial of Capecitabine Plus Oxaliplatin as First-Line Therapy for Advanced Gall Bladder Cancers.
    Asian Pac J Cancer Prev. 2025;26:3761-3767.
    PubMed    
    Abstract available

  39. DE ANGELIS M, Pellegrino F, Scilipoti P, Longoni M, et al
    Real-world impact of cisplatin-based neoadjuvant chemotherapy on bladder cancer survival: a 20-year study.
    World J Urol. 2025;43:636.
    PubMed    
    Abstract available

  40. LIN S, Jiang Y, Xu T, Zhou X, et al
    The incidence and risk factors of urinary tract infections in patients undergoing bladder tumor resection: a systematic review and meta-analysis.
    BMC Urol. 2025;25:267.
    PubMed    
    Abstract available

  41. CAI Y, Zhu C, Shi MH, Zhang JH, et al
    YTHDC2 suppresses bladder cancer by inhibiting SOX2-mediated tumor plasticity.
    Cell Death Dis. 2025;16:765.
    PubMed    
    Abstract available

  42. SHIH V, Yin L, Theodorou E, Dillon R, et al
    A Systematic Literature Review of Real-World Treatment Effectiveness and Economic and Humanistic Burden in Patients With Muscle-Invasive Bladder Cancer Who Underwent Radical Cystectomy.
    Clinicoecon Outcomes Res. 2025;17:729-742.
    PubMed    
    Abstract available

  43. DYRSKJOT L, Black P, Lerner S, Theodorescu D, et al
    Bladder cancer journal as official IBCN partner; strengthening global collaboration in bladder cancer.
    Bladder Cancer. 2025;11:23523735251384859.
    PubMed    


  44. HAWKINS DA, Camacho M, Godbole G, Dell'Oro C, et al
    Comparing quality of life after robot assisted versus open radical cystectomy: A systematic review.
    J Robot Surg. 2025;19:712.
    PubMed    
    Abstract available

  45. MONTORSI F, Moschini M, Rosiello G, Gandaglia G, et al
    Re: Siamak Daneshmand, Michiel S. Van der Heijden, Joseph M. Jacob, et al. TAR-200 for Bacillus Calmette-Guerin-unresponsive High-risk Non-muscle-invasive Bladder Cancer: Results from the Phase IIb SunRISe-1 Study. J Clin Oncol. In press. https://doi.
    Eur Urol Focus. 2025 Oct 25:S2405-4569(25)00286.
    PubMed    


  46. SOLIMAN A, Murad MR, Jabrieh G, AlEdani EM, et al
    A Systematic Review and Meta-Analysis of the Effectiveness and Safety of Immune Checkpoint Inhibitors in Patients With BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer.
    Clin Genitourin Cancer. 2025 Sep 25:102445. doi: 10.1016/j.clgc.2025.102445.
    PubMed    
    Abstract available

  47. ZHU X, Liao D, Huang S, Feng Y, et al
    Letter to the Editor Regarding "Assessing the Influence of Bladder Cancer on Upper Tract Urothelial Carcinoma Prognoses Following Radical Nephroureterectomy: A Retrospective, Propensity Score-Based Multicenter Cohort Study".
    Ann Surg Oncol. 2025 Oct 25. doi: 10.1245/s10434-025-18611.
    PubMed    


  48. MATSUMURA N, Mandai M
    PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; durvalumab, cemiplimab, zongertinib, and taletrectinib for lung cancer, pirtobrutinib and atezolizumab for lymphoma, durvalumab for bladder cancer
    Int J Clin Oncol. 2025 Oct 25. doi: 10.1007/s10147-025-02901.
    PubMed    


  49. QIAN C, Qin J, Lin Z, Wang S, et al
    Single-cell stemness analysis highlights Midkine-LRP1 pathway and identifies new bladder cancer subtypes.
    Cancer Cell Int. 2025;25:376.
    PubMed    
    Abstract available

  50. LIU Z, Xin P, Wu W, Jin M, et al
    ACTG1 driven splicing of P4HB gene enhances EMT and bladder cancer progression.
    NPJ Precis Oncol. 2025;9:330.
    PubMed    
    Abstract available

  51. PARK JY, Kim J, Kim YJ, Kim SH, et al
    Multi-institutional validation of AI models for classifying urothelial neoplasms in digital pathology.
    Sci Rep. 2025;15:37215.
    PubMed    
    Abstract available

  52. BERNSTEIN AN
    Sex-based differences in bladder cancer: Functional, oncologic, and biological considerations.
    Urol Oncol. 2025 Oct 23:S1078-1439(25)00406.
    PubMed    


  53. WANG C, Shaish H, Luk L
    Bladder Cancer and Vesical Imaging-Reporting and Data System: An Updated Review.
    Radiol Clin North Am. 2025;63:923-940.
    PubMed    
    Abstract available

  54. HASSAN N, Michaud E, Mansure JJ, Farag M, et al
    The clinical relevance of tertiary lymphoid structures in assessing treatment response in muscle invasive bladder cancer.
    Int J Radiat Oncol Biol Phys. 2025 Oct 22:S0360-3016(25)06329.
    PubMed    
    Abstract available

  55. LOMOIO U, Mazza T, Veltri P, Guzzi PH, et al
    E-ABIN: an explainable module for anomaly detection in biological networks.
    NAR Genom Bioinform. 2025;7:lqaf135.
    PubMed    
    Abstract available

  56. BAKULA M, Hudolin T, Kulis T, Zekulic T, et al
    Sequential intravesical Bacillus Calmette-Guerin and mitomycin C applied with electromotive drug administration therapy for non-muscle invasive bladder cancer.
    Front Oncol. 2025;15:1682918.
    PubMed    
    Abstract available

  57. ALSALMI OA, Alqurashi TS, Alsalmi BA, Aljohani AI, et al
    Awareness, knowledge, and willingness about early detection of bladder cancer in Saudi Arabia: a cross-sectional study.
    Transl Androl Urol. 2025;14:2498-2509.
    PubMed    
    Abstract available

  58. LV L, Wang J, Li L
    En bloc transurethral resection versus conventional transurethral resection for non-muscle invasive bladder cancer: a systematic review and meta-analysis.
    Transl Androl Urol. 2025;14:2593-2605.
    PubMed    
    Abstract available

  59. BEN L, Wang J, Wu P
    Mechanistic study of GALNT16 promoting malignant progression and metastasis in bladder cancer: functional analysis and experimental validation.
    Transl Androl Urol. 2025;14:2481-2497.
    PubMed    
    Abstract available

  60. LI S, Su D, Lin J, Song H, et al
    [Prognostic analysis of laparoscopic simultaneous radical cystectomy and nephroureterectomy].
    Beijing Da Xue Xue Bao Yi Xue Ban. 2025;57:961-966.
    PubMed    
    Abstract available

  61. GRANDE E, Bellmunt J, Hussain SA, Al Mansour MM, et al
    Guiding first-line treatment decisions in advanced urothelial carcinoma: a global survey.
    Oncologist. 2025;30:oyaf333.
    PubMed    
    Abstract available

  62. PUENTE J, Rodriguez-Vida A, Sevillano E, Estevez SV, et al
    SEOM-SOGUG clinical guideline for urothelial cancer (2025).
    Clin Transl Oncol. 2025;27:4142-4159.
    PubMed    
    Abstract available

  63. NAGUMO Y, Mathis BJ, Nishiyama H
    First-line treatment options for metastatic urothelial carcinoma: balancing efficacy, safety, and individual values and preferences through shared decision making.
    Int J Clin Oncol. 2025;30:2161-2167.
    PubMed    
    Abstract available

  64. CHOKUNONGA E, Borok M, Danso AP, Chirenje M, et al
    Trends in the incidence of cancers of the male genital system and urinary bladder in Harare, Zimbabwe, 1990-2019.
    Cancer Causes Control. 2025;36:1579-1587.
    PubMed    
    Abstract available

  65. WU Y, Zhang Y, Han J, Jiang Y, et al
    Nanozyme-Based Biomimetic Intelligent Immune Organelles for the Treatment of Bladder-Metastasized Tumors.
    Adv Mater. 2025;37:e11181.
    PubMed    
    Abstract available

  66. PAU S, Patel A, Yap S, Eglinton T, et al
    Colovesical Fistula Management and the Role of Cystoscopy: A Single Institution Experience.
    ANZ J Surg. 2025;95:2148-2154.
    PubMed    
    Abstract available

  67. KAUR N, Khanna M, Kaur A, Gill KS, et al
    The expression of p53 in urothelial carcinoma of bladder: An immunohistochemical study.
    Indian J Pathol Microbiol. 2025;68:492-497.
    PubMed    
    Abstract available

  68. YAGI F, Akita H, Matsumoto K, Kosaka T, et al
    A case of plasmacytoid urothelial carcinoma with characteristic radiological findings.
    Abdom Radiol (NY). 2025;50:5376-5381.
    PubMed    
    Abstract available

  69. YANG T, Kong SP, Xu QL, Zhan CX, et al
    CKS2 promotes the malignant phenotypes of bladder cancer cells via PI3K/AKT signaling pathway activation.
    Cell Cycle. 2025 Nov 7:1-15. doi: 10.1080/15384101.2025.2586117.
    PubMed    
    Abstract available

  70. SUN J, Shi Y, Yu K, Huang S, et al
    Hypoxia-Induced Histone Lactylation Drives Cisplatin Resistance in Bladder Cancer by Promoting RBM15-Dependent m(6)A Methylation of IGFBP3.
    Research (Wash D C). 2025;8:0970.
    PubMed    
    Abstract available

  71. LEDESMA L, Pullenayegum E
    Intercept Estimation of Semi-Parametric Joint Models in the Context of Longitudinal Data Subject to Irregular Observations.
    Biom J. 2025;67:e70088.
    PubMed    
    Abstract available

  72. YANG B, Wei Y, Liu S, Wang J, et al
    Integration of Single-cell and bulk RNA sequencing data uncovers lymphatic metastasis-related prognostic genes and a predictive model in bladder cancer.
    Sci Rep. 2025;15:38973.
    PubMed    
    Abstract available

  73. LI W, Lv R, Su H, Fan Y, et al
    Clinicopathological significance of Kruppel-like factor 15 and epithelial-to-mesenchymal transition related factors in bladder cancer.
    Sci Rep. 2025;15:38862.
    PubMed    
    Abstract available

  74. TANG Z, Peng J, Pan X, Kong Y, et al
    An Anoikis-Based Prognostic Signature Identifies MYC as a Key Regulator of Malignancy and Immunotherapy Resistance in Bladder Cancer.
    Front Biosci (Landmark Ed). 2025;30:45386.
    PubMed    
    Abstract available

  75. TAYLOR N, Heering G, Icht O, Kozlova D, et al
    Changing Trends in Bladder Cancer Epidemiology in the Israeli Population: 1996-2016.
    Isr Med Assoc J. 2025;27:684-690.
    PubMed    
    Abstract available

  76. ZHOU T, Liu H, Shen Y, Shao S, et al
    Real-world evaluation of the efficacy and safety of disitamab vedotin (RC48) in urothelial carcinoma.
    BMC Urol. 2025;25:276.
    PubMed    
    Abstract available

  77. PORRECA A, Marino F, Marchi D, Giampaoli M, et al
    The Role of Holmium Laser Enucleation of the Prostate in Reducing the Risk of Bladder Cancer Recurrence and Progression.
    J Endourol. 2025 Nov 5. doi: 10.1177/08927790251390869.
    PubMed    
    Abstract available

  78. FILON M, Schmidt B
    Erratum: New Treatment Options for Non-Muscle-Invasive Bladder Cancer.
    Am Soc Clin Oncol Educ Book. 2025;45:e471942CX1.
    PubMed    


  79. PENG Z, Yang J, Jia R, Wu T, et al
    Sphingolipid Metabolism Dysregulation Drives Immune Microenvironment Remodeling and Predicts Prognosis in Bladder Cancer.
    Int J Genomics. 2025;2025:6085216.
    PubMed    
    Abstract available

  80. GUO J, Fan Z, Li D, Chen Q, et al
    Parameter-driven habitat imaging based on intravoxel incoherent motion MRI for preoperative prediction of muscle invasion in bladder cancer.
    Cancer Imaging. 2025;25:125.
    PubMed    
    Abstract available

  81. ZHANG H, Huang W, Cai Z, Mou S, et al
    Correction: CCDC137 knockdown suppresses bladder cancer progression by downregulating SCD.
    J Transl Med. 2025;23:1225.
    PubMed    


  82. YOU C, Fang Q, Qing L, Xiao X, et al
    JUN-ENPP1-cGAS-STING axis mediates immune evasion and tumor progression in bladder cancer.
    J Transl Med. 2025;23:1222.
    PubMed    
    Abstract available

  83. MASONE MC
    Mitochondrial metabolic alterations fuel bladder cancer initiation.
    Nat Rev Urol. 2025 Nov 4. doi: 10.1038/s41585-025-01110.
    PubMed    


  84. FENG Z, Zhang B, Liu Y, Yang F, et al
    Decoding bladder cancer aggressiveness: A proteomic, phosphoproteomic and metabolomic approach.
    J Proteomics. 2025;323:105553.
    PubMed    
    Abstract available

  85. STERNBERG CN, Squires P, Song Y, Wu A, et al
    Evaluation of Event-Free Survival as a Surrogate Endpoint for Overall Survival in Muscle-Invasive Bladder Cancer Following Neoadjuvant Treatment: A Systematic Review and Meta-Analysis.
    Oncol Ther. 2025 Nov 4. doi: 10.1007/s40487-025-00399.
    PubMed    
    Abstract available

  86. XU Y, Wang X, Wang X, Li K, et al
    Integrating single-cell transcriptomics and machine learning reveals 4-aminobiphenyl exposure signatures and novel diagnostic biomarkers in bladder cancer.
    Discov Oncol. 2025;16:2023.
    PubMed    
    Abstract available

  87. REN JW, Ye JJ, Bai YJ, Han P, et al
    The prognostic value of circadian syndrome in non-muscle-invasive bladder cancer: a retrospective cohort study.
    Int J Surg. 2025 Nov 4. doi: 10.1097/JS9.0000000000003740.
    PubMed    
    Abstract available

  88. XU X, Ding Y, Guo X, Cao J, et al
    Global hotspots and trends in robotics of bladder cancer: A bibliometric and visualized analysis.
    Urologia. 2025 Nov 4:3915603251388758. doi: 10.1177/03915603251388758.
    PubMed    
    Abstract available

  89. YANG G, Zhu X, Wei W, Yin X, et al
    Unlocking the role of prostate transmembrane androgen inducible protein 1 in gemcitabine resistance: modulation of P38-mitogen-activated protein kinase/C-C motif chemokine ligand 2 and M2 macrophage polarization in bladder cancer.
    Anticancer Drugs. 2025 Oct 16. doi: 10.1097/CAD.0000000000001769.
    PubMed    
    Abstract available

  90. LEE H, So SW, Han JH, Yuk HD, et al
    The staging of re-TURB is crucial in predicting the response to BCG therapy in patients with T1 high-grade bladder cancer.
    Investig Clin Urol. 2025;66:509-515.
    PubMed    
    Abstract available

  91. RAMASAMY RP, Chai CA, Cormio A, Rajandram R, et al
    Evaluating diagnostic performance of urinary biomarkers in the surveillance of non-muscle invasive bladder carcinoma: A systematic review.
    Investig Clin Urol. 2025;66:482-490.
    PubMed    
    Abstract available

  92. KIM KH, Phan DTT, Ha HK, Jung EH, et al
    Treatment strategies for cisplatin-ineligible metastatic bladder cancer: Emerging therapies and future perspectives.
    Investig Clin Urol. 2025;66:471-481.
    PubMed    
    Abstract available

  93. LI KM, Liu ML, Wu SF, Hong RP, et al
    [Association between HER2 overexpression and recurrence rate in patients with non-muscle-invasive bladder cancer following anthracycline-based intravesical instillation therapy].
    Zhonghua Bing Li Xue Za Zhi. 2025;54:1193-1198.
    PubMed    
    Abstract available

  94. GOLOMB D, Atamna F, Leonov Polak M, Avda Y, et al
    Cumulative smoking exposure correlates with progression in high-grade T1 bladder cancer.
    Urologia. 2025 Nov 3:3915603251390744. doi: 10.1177/03915603251390744.
    PubMed    
    Abstract available

  95. WANG Y, Li C
    A network toxicology approach to elucidate shared oncogenic pathways of Aristolochic acids in prostate, kidney, and bladder cancers.
    Toxicol Res (Camb). 2025;14:tfaf150.
    PubMed    
    Abstract available

  96. WANG L, Yang J, Xu Z, Tao B, et al
    Comprehensive analysis of single-cell and bulk transcriptomes reveals key B-cell genes and immune microenvironment regulation in bladder cancer.
    Front Immunol. 2025;16:1600254.
    PubMed    
    Abstract available

  97. HAO L, Zhao Y, Li ZG, He HG, et al
    [Retracted] Tumor necrosis factor-related apoptosis-inducing ligand inhibits proliferation and induces apoptosis of prostate and bladder cancer cells.
    Oncol Lett. 2025;31:1.
    PubMed    
    Abstract available

  98. ALI HS, Bilal E, Noor H, Khalid M, et al
    Critical appraisal of "A cross-sectional study on the effects of intravesical BCG on urinary microbiota in bladder cancer patients".
    Ann Med Surg (Lond). 2025;87:7786-7787.
    PubMed    


  99. GAMMELL F, Li J, Elco C, Plavicki J, et al
    THRESHOLD: a comprehensive transcriptomic analysis tool for evaluating gene saturation and impact in disease progression.
    NAR Cancer. 2025;7:zcaf032.
    PubMed    
    Abstract available

  100. ZHANG D, Chen B, Ye J, Bai Y, et al
    Integrated assessment of non-invasive diagnostic tools for bladder cancer: a network meta-analysis.
    Front Oncol. 2025;15:1649420.
    PubMed    
    Abstract available

  101. SUN Y, Ding M, Sun J, Zhang Q, et al
    Novel Biomarkers for Lymph Node Metastasis and Prognosis of Bladder Cancer by Bioinformatics Analysis.
    ACS Omega. 2025;10:50124-50138.
    PubMed    
    Abstract available

  102. ENEMOH O, Adefehinti M, Sanni QA, Ogunbadejo HA, et al
    Exploring the Need for a Consensus Guideline for the Management of Non-Muscle-Invasive Bladder Cancer: A Scoping Review.
    Cureus. 2025;17:e93553.
    PubMed    
    Abstract available

  103. ZHAI J, Tan R, Yuan S, Che B, et al
    Unveiling tectorigenin: A novel ferroptosis inducer targeting EGFR in bladder cancer.
    Phytomedicine. 2025;148:157419.
    PubMed    
    Abstract available

  104. ABOU CHAKRA M, Duquesne I, Mima M, Ohlander S, et al
    Male reproductive and sexual health outcomes following intravesical therapy for non-muscle invasive bladder cancer.
    World J Urol. 2025;43:659.
    PubMed    
    Abstract available

  105. LUNA J, Kampe EOI, Aga-Barfknecht H, Lehne M, et al
    Epidemiology, treatment patterns and effectiveness of adherence to Bacillus Calmette-Guerin therapy in intermediate and high-risk non-muscle-invasive bladder cancer patients: a retrospective cohort analysis using German health claims data.
    World J Urol. 2025;43:661.
    PubMed    
    Abstract available

  106. INOUE S, Miszczyk M, Suleja A, Matsukawa A, et al
    Urinary biomarkers for immunotherapy response in urothelial carcinoma: current status and future outlook.
    Expert Rev Mol Diagn. 2025;25:793-799.
    PubMed    
    Abstract available

  107. SONG Y, Jiang S, Peng Y, Du Y, et al
    FGFR3 alteration sites and response rate to FGFR inhibitors in urothelial carcinoma.
    Pharmacol Res. 2025;221:107968.
    PubMed    
    Abstract available

  108. FARRE A, Huguet J, Basile G, Dieguez L, et al
    Oncological outcomes for patients with European Association of Urology definitions of BCG failure treated with radical cystectomy.
    Actas Urol Esp (Engl Ed). 2025;49:501834.
    PubMed    
    Abstract available

  109. POLVERINO F, Marmiroli A, Longoni M, Le QC, et al
    The Effect of Chronic Liver Disease on Adverse In-Hospital Outcomes After Radical Cystectomy and Ileal Conduit Urinary Diversion.
    Ann Surg Oncol. 2025;32:10328-10334.
    PubMed    
    Abstract available

  110. NSAIR A, Malshy K, Hijazi H, Eigner E, et al
    Impact of neoadjuvant chemotherapy on short-term complications following robotic radical cystectomy.
    Urologia. 2025;92:603-610.
    PubMed    
    Abstract available

  111. AKHTAR SN, Gudbrandsdottir G, Aarsaether E, Carlsen B, et al
    Presentation and survival for urachal cancer: Findings from a nationwide multicenter cohort study in Norway.
    Urologia. 2025;92:595-602.
    PubMed    
    Abstract available

  112. MEMBRIBES SC, Nally E, Jackson-Spence F, Graham C, et al
    Established and emerging biomarkers approaches in urothelial carcinoma.
    Expert Rev Anticancer Ther. 2025;25:1235-1241.
    PubMed    
    Abstract available

  113. MARMIROLI A, Longoni M, Le QC, Falkenbach F, et al
    Adverse In-hospital Outcomes According to Pelvic Lymph Node Dissection at Partial Cystectomy.
    Ann Surg Oncol. 2025;32:10279-10284.
    PubMed    
    Abstract available

  114. MALSHY K, Steinmetz A, Messing EM
    Implementation challenges of single-instillation intravesical chemotherapy following transurethral resection of bladder tumor.
    Expert Rev Anticancer Ther. 2025;25:1227-1234.
    PubMed    
    Abstract available

  115. YIP W, Jaime-Casas S, Kothari A, Sullivan M, et al
    Urothelial carcinoma: Perioperative considerations from top to bottom.
    CA Cancer J Clin. 2025;75:528-551.
    PubMed    
    Abstract available

  116. DING X, Zhang E, Huang Z, Li X, et al
    Glutamine metabolism reprogramming promotes bladder cancer progression via PYCR1: a multi-omics and functional validation study.
    J Transl Med. 2025;23:1277.
    PubMed    
    Abstract available

  117. ZOU XC, Wang B, Yu ZJ, Chao HC, et al
    A radiomics-driven machine learning model for predicting bladder cancer prognosis identifies genes associated with radiomic features.
    Clin Exp Metastasis. 2025;42:63.
    PubMed    


  118. LETH KIRSTEN SL, Loff AM, Christensen SH, Munk T, et al
    Low albumin-corrected plasma zinc is common among patients with bladder cancer undergoing cystectomy.
    Clin Nutr ESPEN. 2025 Nov 11:S2405-4577(25)02999.
    PubMed    
    Abstract available

  119. GAO L, Chen J, Shang K, Wang G, et al
    MicroRNAs in bladder cancer: biogenesis, function, and therapeutic strategies.
    Int J Surg. 2025 Nov 13. doi: 10.1097/JS9.0000000000003947.
    PubMed    
    Abstract available

  120. MAMDOUH S, Aboushousha T, Hemida E, El-Araby RE, et al
    Role of microRNA-183 based theranostics through targeting TPM1 in bladder cancer.
    Discov Oncol. 2025;16:2100.
    PubMed    
    Abstract available

  121. DOSHI H, Geynisman DM
    Checkmate 274: expanding treatment options for muscle-invasive bladder cancer.
    Transl Androl Urol. 2025;14:2786-2791.
    PubMed    


  122. YU L, Gao S, Li D, Chen X, et al
    Identification of molecular subtypes and prognostic risk model of glucocorticoid-related lncRNAs in bladder cancer to evaluate prognosis and immunological characteristics.
    Transl Androl Urol. 2025;14:3277-3297.
    PubMed    
    Abstract available

  123. HUANG X, Sun Y, Tong H, Zhu J, et al
    Ursolic acid sensitizes bladder cancer to gemcitabine chemotherapy by concurrently targeting PI3K/AKT and JNK pathways.
    Transl Androl Urol. 2025;14:2902-2916.
    PubMed    
    Abstract available

  124. LIU T, Yao Y, Huang J, Ji J, et al
    A log odds of positive lymph nodes (LODDS)-based nomogram for survival prediction in elderly bladder cancer patients after radical cystectomy: development and validation using SEER and Chinese cohorts.
    Transl Androl Urol. 2025;14:2873-2884.
    PubMed    
    Abstract available

  125. ALBAKR A, Narayan VM, Tyson M, Shoskes D, et al
    Pharmacotherapy for bladder spasm and irritative lower urinary tract symptoms associated with intravesical therapy for bladder cancer: a review of available evidence.
    Transl Androl Urol. 2025;14:3402-3412.
    PubMed    
    Abstract available

  126. DAI F, He Y, Huang X, Lin K, et al
    Integrating transcriptomics, single-cell omics, and deep learning-based histopathological features to identify OLFML3 in bladder cancer.
    Transl Androl Urol. 2025;14:3097-3113.
    PubMed    
    Abstract available

  127. NINOMIYA S, Ishiguro Y, Hasumi H, Jikuya R, et al
    The Role of FGFR3 in the Progression of Bladder Cancer.
    Cancers (Basel). 2025;17:3588.
    PubMed    
    Abstract available

  128. GABRIEL PE, Horowitz A, Guerrero-Ramos F, Soria F, et al
    Therapeutic Intensification Based on Immune Checkpoint Inhibitors in Non-Muscle Invasive Bladder Cancer: State of the Art and Future Perspectives.
    Cancers (Basel). 2025;17:3555.
    PubMed    
    Abstract available

  129. GUSZCZ T, Lukaszewski Z, Gorodkiewicz E, Hermanowicz A, et al
    Potential of Proteases in the Diagnosis of Bladder Cancer.
    Cancers (Basel). 2025;17:3460.
    PubMed    
    Abstract available

  130. YANG Z, Song F, Zhong J
    Urinary Biomarkers in Bladder Cancer: FDA-Approved Tests and Emerging Tools for Diagnosis and Surveillance.
    Cancers (Basel). 2025;17:3425.
    PubMed    
    Abstract available

  131. PATEL K, Radcliffe R
    Evaluating the Readability and Quality of Bladder Cancer Information from AI Chatbots: A Comparative Study Between ChatGPT, Google Gemini, Grok, Claude and DeepSeek.
    J Clin Med. 2025;14:7804.
    PubMed    
    Abstract available

  132. BUTT UA, De Biase D
    The Urinary Microbiota and the Gut-Bladder Axis in Bladder Cancer.
    Int J Mol Sci. 2025;26:10558.
    PubMed    
    Abstract available

  133. ZHOU H, Lin S, Sun C, Ge Z, et al
    Evaluation of the diagnostic performance of YiDiXie tests in urothelial carcinoma.
    Eur J Med Res. 2025;30:1113.
    PubMed    
    Abstract available

  134. XIE H, Dong C, Li Y, Guo J, et al
    XGBoost-based urinary microbial signatures enable non-invasive diagnosis and prognosis for urothelial carcinoma.
    BMC Microbiol. 2025;25:732.
    PubMed    
    Abstract available

  135. GRIEBSCH I, Shrestha S, Lotan Y, Ng CF, et al
    The Impact of Intravesical Instillations on Quality of Life in Patients with Non-Muscle-Invasive Bladder Cancer: A Systematic Review.
    Oncol Ther. 2025 Nov 13. doi: 10.1007/s40487-025-00375.
    PubMed    
    Abstract available

  136. WEITZNER AS, Grutman AJ, Arbuiso A, Cheaib J, et al
    Gender-based Differences in Psychosocial Well-being Among Bladder Cancer Survivors.
    Eur Urol Oncol. 2025 Nov 11:S2588-9311(25)00239.
    PubMed    
    Abstract available

  137. DAVIES-TEYE BB, Seo D, Johnson A, Stuart J, et al
    Trends in Treatment Patterns and Outcomes Among Patients Diagnosed With Nonmuscle-Invasive Bladder Cancer in the United States.
    Clin Genitourin Cancer. 2025 Aug 29:102424. doi: 10.1016/j.clgc.2025.102424.
    PubMed    
    Abstract available

  138. ZHU T, Luo W, Zhang Y, Liang Z, et al
    Methylparaben and propylparaben promote bladder cancer invasion via MMP2 and PPARG modulation.
    Ecotoxicol Environ Saf. 2025;306:119383.
    PubMed    
    Abstract available

  139. REN JW, Bai YJ, Han P
    Cancer-specific chronotherapy and insights into non-muscle-invasive bladder cancer: a correspondence.
    Int J Surg. 2025 Nov 12. doi: 10.1097/JS9.0000000000003998.
    PubMed    


  140. VARADI M, Horvath O, Soos E, Csizmarik A, et al
    Combining molecular patterns and clinical data for better immune checkpoint inhibitor prediction in metastatic urothelial carcinoma.
    Cancer Immunol Immunother. 2025;74:370.
    PubMed    
    Abstract available

  141. HUANG Y, Chen C, Su M, Li D, et al
    MCUB Inhibits PRKN-Dependent Mitophagic Degradation of PD-L1 to Promote Immune Evasion in Bladder Cancer.
    Adv Sci (Weinh). 2025 Nov 12:e14764. doi: 10.1002/advs.202514764.
    PubMed    
    Abstract available

  142. TANTRAY MA, Khan TA, Malik SA, Para SA, et al
    Predicting Histopathological Outcomes from Cystoscopic Findings in Newly Diagnosed Bladder Cancer: A Prospective Observational Study.
    Cureus. 2025;17:e94251.
    PubMed    
    Abstract available

  143. ZHANG L, Cao L, Huang L, Wang J, et al
    Associations of systemic immune-inflammation index, product of platelet, and neutrophil count, with the pathological grade of bladder cancer.
    Can J Urol. 2025;32:457-468.
    PubMed    
    Abstract available

  144. HOFFMAN A, Kochavi E, Amiel GE
    Cryotherapy for non-muscle invasive bladder cancer-preliminary results in an animal model.
    Can J Urol. 2025;32:423-432.
    PubMed    
    Abstract available

  145. LYU J, Yue R, Zhu Y, Tian Y, et al
    Association of urinary tract infection and low albumin/globulin ratio with chemoresistance to gemcitabine-cisplatin in advanced urothelial carcinoma.
    Can J Urol. 2025;32:411-422.
    PubMed    
    Abstract available

  146. KOHLER J, Buck L, Hugelmann K, Incesu RB, et al
    Expanding the role of robotic surgery: Non-inferiority of robot-assisted radical cystectomy in overweight patients with bladder cancer.
    J Robot Surg. 2025;20:9.
    PubMed    
    Abstract available

  147. ZHANG B, Yao Z, Zhou Z, Zhang Y, et al
    The serum platelet-to-lymphocyte ratio as a predictor of outcomes in bladder cancer patients: an updated meta-analysis.
    Sci Rep. 2025;15:39502.
    PubMed    
    Abstract available

  148. PEYTON CC, Kates M, Nadkarni A, Dhanda R, et al
    Patient-reported outcomes following UGN-102 treatment in low-grade intermediate-risk non-muscle invasive bladder cancer: An analysis of three clinical trials.
    Urol Pract. 2025 Nov 11:101097UPJ0000000000000917.
    PubMed    
    Abstract available

  149. CAI LK, Yang X, Tan ZY, Bai RJ, et al
    [Application of NeoVI-RADS scoring in patients with bladder cancer undergoing neoadjuvant therapy].
    Zhonghua Wai Ke Za Zhi. 2025;63:1111-1117.
    PubMed    
    Abstract available

  150. SHAO Y, Yu Q, Zhu J, Wang X, et al
    Construction and mechanistic exploration of a ferroptosis related gene based prognostic model for cisplatin resistance in bladder cancer.
    Comput Methods Biomech Biomed Engin. 2025.
    PubMed    
    Abstract available

  151. MICHAEL SN, Makkar A, Nagaraju S, Sood R, et al
    A randomized study comparing outcomes of intravesical Gemcitabine, Mitomycin C (as hyperthermic intravesical chemotherapy-HIVEC) and Bacillus-Calmette Guerin in intermediate and high-risk non-muscle invasive bladder cancer.
    Urologia. 2025 Nov 11:3915603251388204. doi: 10.1177/03915603251388204.
    PubMed    
    Abstract available

  152. SCHMITZ J, Bartkowiak AL, Rose M, Kolks N, et al
    Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107.
    Mol Oncol. 2025 Nov 11. doi: 10.1002/1878-0261.70148.
    PubMed    
    Abstract available


  153. Correction to "M2 Tumor Associate Macrophage- (TAM-) Derived lncRNA HISLA Promotes EMT Potential in Bladder Cancer".
    J Oncol. 2025;2025:9754691.
    PubMed    
    Abstract available

  154. ZHAO B, Huang Y, Shi J, Zhou X, et al
    XPC Deficiency Activate Cisplatin-Mediated Autophagy in Bladder Cancer by Limiting Novel PHRF1-Mediated Ubiquitination of the p53 Protein.
    Adv Sci (Weinh). 2025 Nov 11:e17563. doi: 10.1002/advs.202517563.
    PubMed    
    Abstract available

  155. LI S, Zhang J, Cheng C, Dai Y, et al
    Utility of node-RADS in preoperatively detecting pelvic lymph node metastasis in bladder cancer.
    World J Urol. 2025;43:676.
    PubMed    
    Abstract available

  156. BAI J, Huang Y, Chen B, Ran B, et al
    Prognostic value of the systemic immune-inflammation index in bladder cancer: an update evidence-based analysis.
    Front Oncol. 2025;15:1707657.
    PubMed    
    Abstract available

  157. MALSHY K, Messing EM
    Can urinary tumor DNA be used to assess the risk of recurrence in patients with non-muscle invasive bladder cancer?
    Bladder Cancer. 2025;11:23523735251395843.
    PubMed    


  158. LUO X, Zhang Y, Wang W, Xiong Y, et al
    Analysis of global burden of male kidney, prostate, and bladder cancers: comparative study of relevant risk factors from 1990 to 2019.
    Int J Surg. 2025 Nov 10. doi: 10.1097/JS9.0000000000003783.
    PubMed    


  159. MOHTADI S, Molavinia S, Shariati S, Mahdavinia M, et al
    Exploring the Effectiveness of Sitagliptin to Enhance Cisplatin Chemosensitivity in HTB-9 Bladder Cancer Cells.
    J Biochem Mol Toxicol. 2025;39:e70584.
    PubMed    
    Abstract available

  160. IKEHATA Y, Nishiyama N, Ishida S, Kitamura H, et al
    Evaluation of the utility of molecular subtype classification by immunohistochemistry in bladder cancer undergoing radical cystectomy: a retrospective cohort study.
    Jpn J Clin Oncol. 2025 Nov 5:hyaf167. doi: 10.1093.
    PubMed    
    Abstract available

  161. SCILIPOTI P, Zaurito P, Longoni M, de Angelis M, et al
    Impact of timing between neoadjuvant therapy and radical cystectomy on survival in muscle-invasive bladder cancer.
    World J Urol. 2025;43:673.
    PubMed    
    Abstract available

  162. SHEN H, Zheng F, Tang X, Ma Z, et al
    Constructing a bladder cancer prognostic model related to exosome using machine learning and identifying THBS1 as a potential target.
    Cancer Cell Int. 2025;25:392.
    PubMed    
    Abstract available

  163. ZHAO S, Li R, Tian T, Zhang J, et al
    Single-cell RNA sequencing identifies potential critical prognostic biomarkers in bladder carcinoma.
    Sci Rep. 2025;15:39105.
    PubMed    
    Abstract available

  164. PEREZ COSTOYA C, Granell Suarez C, Alvarez Munoz V, Gomez Farpon A, et al
    Management of nephrogenic adenoma in pediatric patients with multiple urological interventions.
    Cir Pediatr. 2025;38:163-166.
    PubMed    
    Abstract available

  165. CHUNG R, Montanaro F, Croll B, Correa A, et al
    Time to change the template: An oncologic appraisal of organ sparing cystectomy in the female patient.
    Urol Oncol. 2025;43:685-692.
    PubMed    
    Abstract available

  166. CALVET F, Blanco Martinez-Illescas R, Muinos F, Tretiakova M, et al
    Sex and smoking bias in the selection of somatic mutations in human bladder.
    Nature. 2025;647:436-444.
    PubMed    
    Abstract available

  167. TOMITA Y, Ye DW, Fujii A, Takeuchi N, et al
    Nivolumab plus gemcitabine-cisplatin for previously untreated unresectable or metastatic urothelial carcinoma: an Asian subgroup analysis from the global phase 3 CheckMate 901 trial.
    Urol Oncol. 2025;43:696.
    PubMed    
    Abstract available

  168. NATIV O, Sadiq S, Williams A, Reid G, et al
    Utilization of intravesical chemotherapy following TURBT: A pre-implementation analysis of American College of Surgeon Commission on Cancer GU quality measures.
    Urol Oncol. 2025;43:696.
    PubMed    
    Abstract available

  169. EBNER B, Hirsch J, Holz A, Volz Y, et al
    Association of interleukin-6 serum levels with local tumor stage and lymph node metastasis of urothelial carcinoma.
    Urol Oncol. 2025;43:693.
    PubMed    
    Abstract available

  170. HAMMOUDA K, Tokuyama N, Corredor G, Pathak T, et al
    AI-informed computational pathology classifier predicts outcomes across treatment modalities in muscle-invasive urothelial carcinoma.
    Cancer Lett. 2025;634:218059.
    PubMed    
    Abstract available

  171. KRISCHAK MK, Bank M, Daignault-Newton S, Semerjian AM, et al
    Assessing the sex-based enrollment gap in urologic oncology clinical trials.
    Urol Oncol. 2025;43:709.
    PubMed    
    Abstract available

  172. DOWNES MR, Lopez-Beltran A, Contieri R, Hansel DE, et al
    International Society of Urological Pathology Consensus Meeting 2024: Working Group 2 Preneoplastic and Precursor Lesions of the Urinary Bladder.
    Am J Surg Pathol. 2025;49:e46-e57.
    PubMed    
    Abstract available

  173. ZHANG X, Guo J, Wang L, Ma Y, et al
    Recurrence risk prediction for non-muscle-invasive bladder urothelial carcinoma using diffusion and clinicopathology features.
    Abdom Radiol (NY). 2025;50:5903-5914.
    PubMed    
    Abstract available

  174. LI S, Liu Y, Wang B, Ning Y, et al
    PICC management for bladder tumor patient with toxic epidermal necrolysis: A crisis intervention case report.
    J Vasc Access. 2025;26:2122-2127.
    PubMed    
    Abstract available

  175. RAPP DE, Zillioux J
    Radical cystectomy in the female patient: The pelvic floor, sexual function, and patient/provider education.
    Urol Oncol. 2025;43:680-684.
    PubMed    
    Abstract available

  176. SUN D, Hadjiiski L, Bruno G, Gormley J, et al
    Evaluating the reliability of large language models for clinical data extraction in bladder cancer prognosis.
    Sci Rep. 2025 Nov 21. doi: 10.1038/s41598-025-27593.
    PubMed    
    Abstract available

  177. KHATAMI F, Sharifkazemi H, Taheri D, Oskouie IM, et al
    Evaluating the Impact of Febuxostat on 5-Aminolevulinic Acid-Based Photodynamic Therapy in Bladder Cancer Cell Lines.
    Photodiagnosis Photodyn Ther. 2025 Nov 19:105286.
    PubMed    
    Abstract available

  178. PICHLER R, Klinglmair G, Binz K, Grande E, et al
    Time to metastasis as a prognostic factor in metastatic urothelial carcinoma: results from the ARON-2 study.
    Clin Exp Metastasis. 2025;43:1.
    PubMed    
    Abstract available

  179. LI H, Dai F, Zhang Y, Li X, et al
    Integrative Deep Learning from H&E Images Reveals Prognostically Distinct Pathology-Based Subtypes in Bladder Cancer.
    Curr Cancer Drug Targets. 2025 Nov 20. doi: 10.2174/0115680096434051251113094536
    PubMed    
    Abstract available

  180. DE MORAES FCA, Rego LHRM, Morbach V, de Lima MPP, et al
    MYC variant at 8q24 increases susceptibility to urinary bladder cancer: a meta-analysis of 53,957 individuals.
    Per Med. 2025 Nov 21:1-9. doi: 10.1080/17410541.2025.2592528.
    PubMed    
    Abstract available

  181. CAO K, Shi Y, Wu B, Shi H, et al
    Single cell RNA sequencing decodes cellular heterogeneity and identifies prognostic immune signatures in bladder cancer microenvironment.
    Discov Oncol. 2025 Nov 20. doi: 10.1007/s12672-025-03878.
    PubMed    


  182. HAN X, Li L, Jia Y, Ai L, et al
    DCUN1D5 is a novel potential biomarker for predicting the prognosis of bladder cancer.
    Discov Oncol. 2025 Nov 20. doi: 10.1007/s12672-025-04082.
    PubMed    
    Abstract available

  183. WEN Y, Ming Z, Xiong Y, Li H, et al
    Small cell size circulating tumor cells predict the prognosis of high-risk non-muscle invasive bladder cancer patients.
    Sci Rep. 2025;15:40909.
    PubMed    
    Abstract available

  184. ARULRAJ K, Aggarwal N, Nayak B, Nayyar R, et al
    Single dose perioperative intravesical instillation of gemcitabine versus mitomycin-C following resection of non-muscle invasive bladder cancer: A randomized controlled trial.
    Urol Oncol. 2025 Nov 19:S1078-1439(25)00443.
    PubMed    
    Abstract available

  185. SUN L, Qin X, Liu D, Zuo W, et al
    A multifunctional M1-like cell vehicle to intravesically deliver ICG for photodynamic therapy of bladder cancer.
    J Control Release. 2025 Nov 18:114428. doi: 10.1016/j.jconrel.2025.114428.
    PubMed    
    Abstract available

  186. SU P, Yang Y, Luo X, Zhang N, et al
    Research progress on the role of AGC kinase family in bladder cancer.
    Discov Oncol. 2025 Nov 20. doi: 10.1007/s12672-025-03977.
    PubMed    
    Abstract available

  187. RINDERKNECHT E, Claps F, Bostrom PJ, Shariat SF, et al
    Is histological grade a useful parameter in muscle-invasive urothelial bladder cancer? Results from a multicenter study on the impact of different grading systems on disease-free survival after upfront radical cystectomy.
    World J Urol. 2025;43:705.
    PubMed    


  188. GABSI H, Audenet F, Verkarre V, Gibault L, et al
    [Unusual bone marrow metastasis revealed by recurrent haematuria].
    Ann Biol Clin (Paris). 2025;83:551-556.
    PubMed    
    Abstract available

  189. ARAI O, Yanagihara Y, Arai H, Watanabe R, et al
    CDH11 Contributes to Bladder Cancer Progression via Regulation of Mitochondrial Energy Metabolism.
    Cancer Med. 2025;14:e71399.
    PubMed    
    Abstract available

  190. IKARASHI D, Nozaki Y, Kikuchi K, Ariga H, et al
    Clinical Outcome and Safety of Combined Radiation Therapy and Maintenance Avelumab for Bladder Cancer: A Case Series.
    Cureus. 2025;17:e94938.
    PubMed    
    Abstract available

  191. LIU L, Wan X, Liu S, Yu C, et al
    Single-cell molecular communications and transcriptional regulatory dynamics of T cell immunotherapy in bladder cancer.
    Genes Dis. 2025;13:101760.
    PubMed    


  192. LIU X, Meng J, Huang B, Jin P, et al
    Vesicocolic fistula in myasthenia gravis patient: A case report.
    Medicine (Baltimore). 2025;104:e45586.
    PubMed    
    Abstract available

  193. CRUPI E, Necchi A, Kamat AM
    Bladder Preservation After Neoadjuvant Therapy for Muscle-invasive Bladder Cancer in the Current Era: Myth and Reality.
    Eur Urol Focus. 2025 Nov 18:S2405-4569(25)00303.
    PubMed    
    Abstract available

  194. CERRATO C, Roupret M, Mir MC
    Circulating Tumor DNA in Muscle-invasive Bladder Cancer: Promise, Pitfalls, and Path Forward.
    Eur Urol Oncol. 2025 Nov 18:S2588-9311(25)00289.
    PubMed    
    Abstract available

  195. SAHIN MF, Akgul M, Akpinar C, Bolat D, et al
    What do the current popular artificial intelligence chatbots offer us regarding patient information? Comparison of responses from the ten most popular chatbots about bladder cancer.
    J Cancer Surviv. 2025 Nov 19. doi: 10.1007/s11764-025-01921.
    PubMed    
    Abstract available

  196. KHAN M, de Groot AG, Cornel EB, van der Heijden AG, et al
    Explainable and likelihood aware AI framework for MRI-based pixel-level bladder tumour prediction.
    Sci Rep. 2025;15:40760.
    PubMed    
    Abstract available

  197. CHEN X, Tian Y, Li T, Zhong Q, et al
    Circ_0003266 suppresses bladder cancer progression by modulating the miR-503-5p/SMAD7/TGF-beta signaling axis.
    Sci Rep. 2025;15:40783.
    PubMed    
    Abstract available

  198. LIU X, Sun S, Wang H, Yang S, et al
    Investigation on the current status of secondary transurethral resection for bladder cancer among Chinese urologists and construction of an acceptance prediction model.
    BMC Urol. 2025;25:292.
    PubMed    
    Abstract available

  199. LU L, Wang F, Wang Z, Guo S, et al
    Immune snapshots along the inflammation-to-cancer road in bladder urothelium.
    Front Immunol. 2025;16:1685237.
    PubMed    
    Abstract available

  200. ZHU Y, Tang Z, Lu Z, Gao D, et al
    Mechanism of active component beta-sitosterol from Myristica fragrans inducing apoptosis in bladder cancer cells via regulating the BCL-2/BAX/caspase-3 pathway.
    Front Oncol. 2025;15:1698721.
    PubMed    
    Abstract available

  201. GAO C, Wang X, Sun Y, An F, et al
    CircPSMA4 as a novel circular RNA enhances the proliferation migration invasion and metabolism of bladder cancer cells through the miR-767-3p/HIF1A pathway.
    Sci Rep. 2025;15:40468.
    PubMed    
    Abstract available

  202. KANG Q, Kong X, Najjar G, Azoitei A, et al
    Loss of p190A RhoGAP induces aneuploidy and enhances bladder cancer cell migration and invasion by modulating actin dynamics.
    Sci Rep. 2025;15:40399.
    PubMed    
    Abstract available

  203. LIU Z, Joshi R, Zhou Z, Liu F, et al
    Self-driven electrical triggering system activates tunneling nanotube highways to enhance drug delivery in bladder cancer therapy.
    Nat Commun. 2025;16:10093.
    PubMed    
    Abstract available

  204. MOYER JA, Mi L, Nguyen MV, Durant AM, et al
    Real-world outcomes of nadofaragene firadenovec for BCG-unresponsive non-muscle-invasive bladder cancer: A multicenter experience.
    Urol Oncol. 2025 Nov 17:S1078-1439(25)00442.
    PubMed    
    Abstract available

  205. RAJA IYUB MJ, Prabhakar P, Sakthivel DK, Chandrasekaran A, et al
    Metastasis Profile and Survival Outcomes of Metastatic Non-Muscle Invasive Bladder Cancer: A National Cancer Database Analysis.
    Clin Genitourin Cancer. 2025;24:102462.
    PubMed    
    Abstract available

  206. SADEGHI S, Lara PN Jr, Necchi A, Gill PS, et al
    Systemic Therapy for Muscle-Invasive Urothelial Carcinoma of the Bladder (Muscle-Invasive Bladder Cancer): Insights From Real-World Data.
    JCO Oncol Pract. 2025 Nov 18:OP2500464. doi: 10.1200/OP-25-00464.
    PubMed    
    Abstract available

  207. WU G, Fan C, Ma X, Yao D, et al
    Utilizing a novel mitochondrial-related gene signature for predicting the prognosis and immunological impact in bladder cancer.
    Discov Oncol. 2025;16:2123.
    PubMed    
    Abstract available

  208. HAN K, Wang F, Wang R, Kong Q, et al
    The CD8(+)/Foxp3(+) ratio, but not the number of OX40(+) TILs, is an independent predictor of tumor recurrence in non-muscle-invasive bladder cancer: a retrospective study.
    PeerJ. 2025;13:e20322.
    PubMed    
    Abstract available

  209. WANG Y, Xiao W, Zhang Z, Wu Y, et al
    The clinical study of preoperative normalized apparent diffusion coefficient of 3.0-T MRI in predicting muscular invasion of bladder cancer.
    BMC Med Imaging. 2025;25:468.
    PubMed    
    Abstract available

  210. LI Y, Zhao B, Gao W, Wu Y, et al
    LDB2 is a novel diagnostic and prognostic biomarker and inhibits bladder cancer metastasis by activating p38 MAPK/ERK1/2/JNK signaling pathway.
    Clin Exp Med. 2025;26:9.
    PubMed    
    Abstract available

  211. CHEN XR, Tan XY, Zhang ZL, Yuan JS, et al
    CHMP4C promote the malignant progression of bladder cancer by regulating the PI3K/AKT pathway.
    Int J Surg. 2025 Nov 14. doi: 10.1097/JS9.0000000000003726.
    PubMed    
    Abstract available

  212. BELSEY J, Lapon J
    Hexaminolevulinate-enhanced photodynamic diagnosis in the management of non-muscle-invasive bladder cancer (NMIBC): the influence of differing European health care payment systems on the potential financial impact of adoption.
    J Med Econ. 2025;28:1999-2009.
    PubMed    
    Abstract available

  213. HOU J, Ding Y, Feng R, Wang Y, et al
    Explainable machine learning model predicts response to adjuvant therapy after radical cystectomy in bladder cancer.
    Front Oncol. 2025;15:1664965.
    PubMed    
    Abstract available

  214. KHEDKAR R, Kaur R, Rane S, Prakash G, et al
    Lymphoepithelioma-like carcinoma of urinary bladder - a rare subtype of urothelial carcinoma: a series of 12 cases.
    Pathologica. 2025;117:409-417.
    PubMed    
    Abstract available

  215. OZ-BEDIR BE, Ercan E, Terzi E, Ozdemir-Sanci T, et al
    Theobromine as a molecular switch: targeting Nrf2 pathway in invasive and non-invasive bladder cancer.
    J Nat Med. 2025 Nov 16. doi: 10.1007/s11418-025-01961.
    PubMed    
    Abstract available

  216. WANG X, Preston A, Aning J, Zhou SM, et al
    Unveiling novel bladder cancer associations from multicentred primary and secondary care electronic health records by machine learning: a case-control study.
    J Biomed Inform. 2025;172:104959.
    PubMed    
    Abstract available

  217. PICCOLINI A, Moretto S, Fasulo V, Uleri A, et al
    Prognostic Role of Different T1 Substaging Systems on Recurrence and Progression in Non-muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis.
    Eur Urol Oncol. 2025 Nov 14:S2588-9311(25)00286.
    PubMed    
    Abstract available

  218. LIN P, Xing Z, Hong Y, Xu H, et al
    Integrin beta4 Drives Immune Evasion and Therapeutic Resistance to PD-1 blockade in Bladder Cancer via MEK/ERK Signaling.
    J Biol Chem. 2025 Nov 13:110941. doi: 10.1016/j.jbc.2025.110941.
    PubMed    
    Abstract available

  219. ISHIKAWA Y, Tanaka H, Kobayashi M, Fujiwara M, et al
    Bladder region-specific analysis of the diagnostic performance of oral 5-aminolevulinic acid fluorescence cystoscopy in non-muscle-invasive bladder cancer.
    Jpn J Clin Oncol. 2025 Nov 15:hyaf171. doi: 10.1093.
    PubMed    
    Abstract available

  220. O'LEARY K
    Liquid biopsy-guided adjuvant therapy in bladder cancer.
    Nat Med. 2025 Nov 14. doi: 10.1038/d41591-025-00065.
    PubMed    


  221. DOU X, Ma X, Meng W, Zhang W, et al
    Retraction Note: HEATR3 involved in the cell proliferation, metastasis and cell cycle development of bladder cancer acts as a tumor suppressor.
    Mol Genet Genomics. 2025;300:105.
    PubMed    


  222. TANG Z, Peng J, Wei Z, Wu S, et al
    Comprehensive analysis of ALYREF gene expression and its correlation with immunotherapy efficacy and circulating tumor cells in bladder cancer.
    Sci Rep. 2025;15:40032.
    PubMed    
    Abstract available

  223. CHEN D, Li X, Zhao G, Zhang C, et al
    Transglutaminase 2 facilitates metastasis of basal-like bladder cancer by sustaining MVP-mediated MAPK/ERK1/2 signaling activation.
    Cancer Lett. 2025;636:218146.
    PubMed    
    Abstract available

  224. BEKIROGLU F, Abdulmajeed A, Aydin A, Laguna P, et al
    The worldwide adoption of enhanced endoscopic imaging in diagnosis and treatment of non-muscle invasive bladder cancer (NMIBC): snapshot analysis from a global survey.
    World J Urol. 2025;43:693.
    PubMed    
    Abstract available

  225. LI J, Bai L, Yan S, Niu J, et al
    Fear of Cancer Recurrence and Its Associated Factors in Bladder Cancer Patients of Different Age Stages: A Cross-Sectional Study.
    Cancer Manag Res. 2025;17:2653-2664.
    PubMed    
    Abstract available

  226. PANG Y, Liu T, Wu X, Chen J, et al
    REV3L as a prognostic biomarker and therapeutic target in bladder urothelial carcinoma.
    Biochem Biophys Res Commun. 2025;790:152909.
    PubMed    
    Abstract available

  227. KUNG ML, Chu TH, Hsieh S, Li CC, et al
    Phenolic zingerone nanoparticles impede cell cycle progression to compete against human urothelial carcinoma.
    Biomed Pharmacother. 2025;192:118675.
    PubMed    
    Abstract available

  228. KHORSANDI N, Porten S, VandenBussche CJ, Greenland N, et al
    Bridging Perspectives: Integrating urologist and cytopathologist insights of urine cytology.
    Semin Diagn Pathol. 2025;42:150960.
    PubMed    
    Abstract available

  229. ZHUANG J, Chen Y, Zheng W, Lian G, et al
    Prediction of HER2 Expression in Urothelial Carcinoma of the Bladder: Are Ultrasound-based Radiomic Features Significant?
    Ultrasound Med Biol. 2026;52:190-200.
    PubMed    
    Abstract available

  230. MATTOS SLDL, Damiao R, Carrerette FB, Carneiro APL, et al
    An anesthetic perspective on transoperative complications in open versus robot-assisted radical cystectomy: a five-year retrospective study.
    Braz J Anesthesiol. 2025;75:844674.
    PubMed    
    Abstract available

  231. PETERSON HM, Keuler NS, Trepanier LA
    Urinary Aromatic Amine Exposures in Pet Dogs With Urothelial Carcinoma and Unaffected Controls.
    Vet Comp Oncol. 2025;23:597-605.
    PubMed    
    Abstract available

  232. LU YC, Chang CH, Ho CH, Hong JH, et al
    SGLT2 inhibitor and urothelial carcinoma incidence in type 2 diabetes patients.
    Diabetes Metab. 2025;51:101694.
    PubMed    
    Abstract available

  233. THOMAS R, Luff JA, Dickey AN, Dillon MN, et al
    Genomic Evaluation of Canine Prostatic Carcinomas as a Model for the Human Disease: or 'UC or not UC - that is the question'.
    Vet Comp Oncol. 2025;23:528-548.
    PubMed    
    Abstract available

  234. BALESTRI I, Ivanova VS, Gasljevic G, von Gunten M, et al
    Exploring the genetic landscape of primary marginal zone lymphoma of the urinary bladder.
    Mod Pathol. 2025 Jul 9:100838. doi: 10.1016/j.modpat.2025.100838.
    PubMed    
    Abstract available

  235. SOTELO M, Pelaez M, Basterretxea L, Varga E, et al
    Avelumab maintenance in advanced urothelial carcinoma: real-world data from Northern Spain (AVEBLADDER study).
    Clin Transl Oncol. 2025;27:4481-4492.
    PubMed    
    Abstract available

  236. DELL'ATTI L
    Management of Bladder Cancer During Pregnancy: A Narrative Review.
    Anticancer Res. 2025;45:4689-4695.
    PubMed    
    Abstract available

  237. RHODES AC, McClintic KA, Witt E, Nwosu I, et al
    Drug-releasing intravesical floating technology for sequential gemcitabine and docetaxel in non-muscle-invasive bladder cancer.
    BJU Int. 2025 Nov 3. doi: 10.1111/bju.70060.
    PubMed    
    Abstract available

  238. ROBERTS IA, Cumberbatch MG, Catto JWF
    Renal, bladder and prostate cancer surgery outcomes with respect to team familiarity.
    BJU Int. 2025 Sep 4. doi: 10.1111/bju.16920.
    PubMed    
    Abstract available

  239. PAYNTER JA, Doherty Z, Qin KR, Pilcher D, et al
    Outcomes after cystectomy in Australian rural and metropolitan hospitals by intensive care admissions.
    BJU Int. 2025;136 Suppl 2.
    PubMed    
    Abstract available

  240. PACE KJC, Kwong JCC, Randhawa H, Ringa M, et al
    Risk of metachronous upper tract urothelial carcinoma following non-muscle-invasive bladder cancer.
    BJU Int. 2025 Nov 19. doi: 10.1111/bju.70085.
    PubMed    
    Abstract available

  241. ABDULMAJEED A, Bekiroglu F, Aydin A, Laguna P, et al
    Guidelines adherence in non-muscle-invasive bladder cancer: a global survey of 3595 participants.
    BJU Int. 2025 Nov 18. doi: 10.1111/bju.70079.
    PubMed    
    Abstract available

  242. ROESSLER N, Miszczyk M, Berger W, Englinger B, et al
    Nectin-4 in bladder cancer: biology and predictive biomarker potential.
    Curr Opin Urol. 2025 Oct 23. doi: 10.1097/MOU.0000000000001354.
    PubMed    
    Abstract available

  243. DREYER T, Jensen JB
    Reply to Behzad Jazayeri, Xuefeng Wang, and Roger Li's Letter to the Editor re: Thomas Dreyer, Simone Brandt, Knud Fabrin, et al. Use of the Xpert Bladder Cancer Monitor Urinary Biomarker Test for Guiding Cystoscopy in High-grade Non-muscle-invasive B
    Eur Urol. 2025 Oct 23:S0302-2838(25)04739-6. doi: 10.1016/j.eururo.2025.
    PubMed    


  244. HUANG H, Ma W, Zeng X, Liu B, et al
    Efficacy and Safety of Disitamab Vedotin Combined with Gemcitabine as Neoadjuvant Therapy in Muscle-invasive Bladder Cancer: An Open-label, Multicenter, Single-arm, Phase 2 Trial.
    Eur Urol. 2025 Nov 4:S0302-2838(25)04768-2. doi: 10.1016/j.eururo.2025.
    PubMed    
    Abstract available

  245. HUSSAIN SA, Catto JWF
    Non-muscle-invasive Bladder Cancer: Many New Options, If You Can Afford Them.
    Eur Urol. 2025 Nov 1:S0302-2838(25)04771-2. doi: 10.1016/j.eururo.2025.
    PubMed    


  246. MORTEZAVI A
    Re: Sasanlimab plus BCG in BCG-naive, High-risk Non-muscle Invasive Bladder Cancer: The Randomized Phase 3 CREST Trial.
    Eur Urol. 2025 Oct 31:S0302-2838(25)04777-3. doi: 10.1016/j.eururo.2025.
    PubMed    


  247. PANEBIANCO V, Briganti A, Efstathiou JA, Galgano SJ, et al
    Multiparametric Magnetic Resonance Imaging and Vesical Imaging-Reporting and Data System (VI-RADS) for Bladder Cancer Diagnosis and Staging: A Guide for Clinicians from the American College of Radiology VI-RADS Steering Committee.
    Eur Urol. 2025 Oct 31:S0302-2838(25)04769-4. doi: 10.1016/j.eururo.2025.
    PubMed    
    Abstract available

  248. MATSUDA K, Tsutsumi M, Kanazawa T, Chihara I, et al
    Limited Response to Enfortumab Vedotin-Pembrolizumab in Three Consecutive Cases of Neoadjuvant Chemotherapy-Resistant Muscle-Invasive Bladder Cancer.
    Int J Urol. 2025;32:1712-1714.
    PubMed    


  249. SALAH S, Ito K, Kita Y, Kobayashi T, et al
    Assessing Response Durability and Survival After Second-Line Pembrolizumab in Advanced Urothelial Carcinoma: A Multicenter Validation of a Risk Model.
    Int J Urol. 2025;32:1569-1575.
    PubMed    
    Abstract available

  250. HONG T, Zhao C, Ji H, Chen H, et al
    Bladder-sparing therapy for high-tumor-burden non-muscle invasive bladder cancer: outcomes from high-tumor-burden NMIBC program.
    Int Urol Nephrol. 2025 Oct 28. doi: 10.1007/s11255-025-04873.
    PubMed    
    Abstract available

  251. RAJA IYUB MJ, Prabhakar P, Sakthivel DK, Chandrasekaran A, et al
    Metastatic non-muscle invasive bladder cancer: histology-specific metastatic patterns and survival in a national cancer database analysis.
    Int Urol Nephrol. 2025 Nov 11. doi: 10.1007/s11255-025-04907.
    PubMed    
    Abstract available

  252. BIAN X, Yang T, Yin H, Hu B, et al
    Efficacy and Safety of BL-B01D1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma: A Phase II Clinical Trial.
    J Clin Oncol. 2025;43:3505-3515.
    PubMed    
    Abstract available

  253. CHUNG D, Kassouf W, Agnihotram R, Alday H, et al
    Outcomes Among Rural and Urban Patients with High-risk NMIBC: Results from the Canadian Bladder Cancer Information System (CBCIS).
    J Urol. 2025 Oct 30:101097JU0000000000004836. doi: 10.1097/JU.0000000000004836.
    PubMed    
    Abstract available

  254. STOVER AM, Mueller D, Carda-Auten J, Hilton A, et al
    Perceived Impact on Patient Routines/Responsibilities for Surgery and a Nonsurgical Primary Treatment Option in Recurrent Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer: Findings From the ENVISION Phase 3 Trial: Erratum.
    J Urol. 2025;214:674.
    PubMed    


  255. DONAT SM, Tin AL, Vickers AJ, Herr H, et al
    Neoadjuvant Chemotherapy With Transurethral Resection for Bladder Preservation: 15-Year Follow-Up of the Retained Bladder.
    J Urol. 2025;214:591-600.
    PubMed    
    Abstract available

  256. FENG Y, Zhou S, Huang S, Yu Z, et al
    Letter: Prolonged Progression-Free Survival, Disease-Free Survival and Cystectomy Avoidance With IL-15 Receptor Lymphocyte-Stimulating Agent NAI Plus Bacillus Calmette-Guerin in Bacillus Calmette-Guerin-Unresponsive Papillary-Only Nonmuscle-Invasive B
    J Urol. 2025 Nov 13:101097JU0000000000004792. doi: 10.1097/JU.0000000000004792.
    PubMed    


  257. WALD G, Lang J, Alkazemi H, Zhang A, et al
    Combination Strategies to Enhance Bacillus Calmette-Guerin Efficacy for Non-Muscle Invasive Bladder Cancer.
    J Urol. 2025 Nov 21:101097JU0000000000004848. doi: 10.1097/JU.0000000000004848.
    PubMed    
    Abstract available

  258. DONG Y, Jiang X, Yang X, Zhang J, et al
    SQLE drives bladder cancer progression by boosting mitochondrial oxidative phosphorylation.
    Oncogene. 2025 Nov 18. doi: 10.1038/s41388-025-03626.
    PubMed    
    Abstract available

  259. QIN N, Chen L, Guo J, Wang J, et al
    Bladder Cancer Burden Across Global, Regional, and National Levels (1990-2021): Associations with Sociodemographic Index, Multidimensional Analyses, and Projections to 2036.
    Urol Int. 2025 Nov 11:1-27. doi: 10.1159/000548815.
    PubMed    
    Abstract available

  260. ZHENG J, Lu S, Zhang Q, Zhang L, et al
    Development and external validation of a FISH-clinical nomogram for predicting overall survival in bladder cancer patients after radical cystectomy.
    BMC Cancer. 2025;25:1648.
    PubMed    
    Abstract available

  261. HU D, Liu H, Li M, Wu W, et al
    Prognostic value of prostate volume and nomograms for predicting recurrence in patients with non-muscle invasive bladder cancer: a multi-institutional study.
    BMC Cancer. 2025;25:1719.
    PubMed    
    Abstract available

  262. ZHAO Y, Ji Z, Sun W, Liu X, et al
    Plasma lipidomics for biomarker identification in non-muscle invasive bladder cancer.
    BMC Cancer. 2025;25:1702.
    PubMed    
    Abstract available

  263. LEE SY, Lee YH, Kim TM, Ha US, et al
    TGF-beta signaling and tumor microenvironment dynamics in bladder cancer progression post-BCG therapy: a longitudinal single-nucleus RNA-seq study.
    BMC Cancer. 2025;25:1735.
    PubMed    
    Abstract available

  264. LLORT ASENS M, Khan I, Fagerholm SC
    beta2-integrins as biomarkers in urothelial cancer.
    PLoS One. 2025;20:e0326015.
    PubMed    
    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.


;